Home > Healthcare > Pharmaceuticals > Finished Drug Form > Carbapenem Market

Carbapenem Market Size

  • Report ID: GMI9836
  • Published Date: Jun 2024
  • Report Format: PDF

Carbapenem Market Size

Carbapenem Market size was valued at around USD 4 billion in 2023 and is estimated to grow at 5% CAGR from 2024 to 2032. Carbapenems are a class of highly effective antibiotics used to treat severe or high-risk bacterial infections.

 

They belong to the beta-lactam family of antibiotics, which work by inhibiting the synthesis of the bacterial cell wall, ultimately leading to the death of the bacteria. Carbapenems are considered broad-spectrum antibiotics because they are effective against a wide variety of gram-positive and gram-negative bacteria, including many strains that are resistant to other antibiotics.
 

The rising incidence of antimicrobial resistance is a significant driver for the market. For instance, according to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the foremost global public health and development threats. In 2019, it is estimated that bacterial AMR directly caused 1.27 million deaths worldwide and contributed to a total of 4.95 million deaths. Therefore, this underscores the urgent need for new and effective antimicrobial agents, driving innovation and investment in the development of novel antibiotics and alternative treatments to combat resistant bacterial infections.
 

Furthermore, high R&D investments in clinical research, growing incidence of hospital-acquired infections, and increased awareness and diagnostic advancements, are driving factors for the market growth.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The carbapenem market size was valued at USD 4 billion in 2023 and is estimated to grow at 5% CAGR from 2024 to 2032, driven by the rising incidence of antimicrobial resistance.

The urinary tract infections segment of the market accounted for USD 1.4 billion in 2023 and will grow at a robust pace through 2032, as carbapenem has a fast-acting bactericidal effect, which helps quickly reduce bacterial load and alleviate symptoms.

U.S carbapenem market size will reach USD 986.9 million by 2032, owing to rising pharmaceutical innovation.

Aurobindo Pharma, Daewoong Pharmaceuticals Co., Ltd, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Kopran Limited, Lupin Limited, Merck & Co., Inc, Novartis AG, and Pfizer Inc. among others.

Carbapenem Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 184
  • Countries covered: 23
  • Pages: 167
 Download Free Sample